The objective of the present study was to evaluate the clinical effects of human atrial natriuretic peptide (hANP) on postoperative cardiopulmonary complications in elderly patients undergoing pulmonary resection for lung cancer.
INTRODUCTION
Lung cancer is generally a disease of older adults, and age has been shown to be an important risk factor for morbidity and mortality after pulmonary resection [1, 2] . Because of these risks, elderly patients have less chance of undergoing curative surgery than younger patients [3, 4] . However, it is inappropriate that elderly patients undergo limited resections solely because of their advanced age. Since no prophylactic strategy has been established, the development of effective treatment for postoperative morbidity is desirable.
Human atrial natriuretic peptide (hANP) consists of 28 amino acids and has a variety of biological effects when used to treat heart failure. It is now known that hANP exhibits a wide range of cardioprotective effects, including anti-fibrosis, anti-hypertrophy, anti-inflammatory and inhibition of sympathetic nerve activity, the renin-angiotensin-aldosterone system and endothelin synthesis [5, 6] . Post-operative cardiopulmonary complications are often due to haemodynamic, neurohormonal and inflammatory changes in the cardiopulmonary interaction. Since the hANP has beneficial effects on haemodynamics, neurohormonal balance and inflammatory changes [7] [8] [9] [10] , it is reasonable to expect that the hANP would protect against post-operative cardiopulmonary complications.
Serum B-type natriuretic peptide (BNP) levels, even in a healthy population, increase with age and any comorbidities [11, 12] , but it has not been established that elderly patients with mildly elevated BNP levels need to be treated. We previously reported that patients in all age groups with elevated pre-operative BNP levels have an increased risk of developing post-operative atrial fibrillation [13] , and elderly patients with elevated pre-operative BNP levels have an increased risk of developing post-operative cardiopulmonary complications following pulmonary resection for lung cancer [14] . The present study aimed to examine the effects of the hANP on post-operative cardiopulmonary complications in such high-risk elderly patients.
MATERIALS AND METHODS

Study design and population
Of the 448 patients who underwent an elective pulmonary resection procedure for lung cancer at Osaka University Graduate School of Medicine and National Toneyama Hospital from April 2008 to March 2010, 56 consecutive elderly patients (≥75 years old) with a pre-operative BNP level of ≥30 pg/ml were included in this open-label, non-randomized and retrospective surveillance study. The cut-off value of BNP (30 pg/ml) was selected based on our previous results [14] , showing that this cut-off value of pre-operative BNP can predict the incidence of post-operative cardiopulmonary complications with high sensitivity and specificity in elderly patients undergoing pulmonary resection for lung cancer. Twelve patients were excluded and the exclusion criteria for the present analysis were cardiac rhythm other than sinus, previous atrial fibrillation, antiarrhythmic drug use, thyroid dysfunction, renal failure requiring haemodialysis and repeated pulmonary resection. Thus, 44 patients were finally enrolled. This study population included partially our previous study population [14] . The results of the patients who did and did not receive low-dose hANP were compared. In the hANP group, the subjects received i.v. hANP just before the induction of systemic anaesthesia (0.025 μg/kg/min without a bolus, Daiichisankyo Pharmaceutical Inc., Tokyo, Japan) for 3 days. Complete preoperative and follow-up data were obtained in all of these patients. The study protocol was approved by the Institutional Review Boards of both institutions, and all patients provided written informed consent before participation (trial registration number: JPRN-UMIN000003631).
Surgical procedure
All patients underwent anterolateral thoracotomy or video-assisted thoracic surgery (VATS). We selected the patients with tumour size of ≤3-4 cm and no lymphadenopathy diagnosed using computed tomography for VATS. In VATS, three access ports were placed through 1-2 cm axillary skin incisions. One of these incisions was extended by 4-5 cm, and the resected lung lobe was removed in a plastic bag without using a rib spreader. Patients requiring conversion from VATS to thoracotomy were classified as open thoracotomy patients due to the operative invasiveness, which might affect post-operative complications. All patients received pre-operative epidural anaesthesia for pain management, which usually remained in place for 2-4 days or until the chest drainage tubes were removed, after which they were switched to oral analgesia. Other post-operative management included early ambulation and low-flow nasal oxygen supplementation, as necessary.
Measurements
Pre-operative evaluations included a detailed history and physical examination, blood gas analysis, 12-lead electrocardiogram, spirometry and determination of serum BNP levels. None of the patients had symptomatic coronary artery disease or congestive heart failure. Physical examinations and electrocardiographic findings at rest were unremarkable in the study population. The C-reactive protein (CRP) levels and white blood cell (WBC) counts were determined before surgery and on Days 1, 3 and 7, and 1 month after surgery. The serum BNP concentrations were determined using a chemiluminescence enzyme immunoassay (MI02 Shionogi BNP, Shionogi Pharmaceutical, Osaka, Japan). Haemodynamic parameters, such as systolic blood pressure, diastolic blood pressure, heart rate and urine volume, were recorded before surgery and for the first 4 days after surgery.
Post-operative complications
All patients were followed-up after surgery, and complications occurring during the same hospitalization as the index procedure were recorded. Cardiopulmonary complications were defined as described previously [14] and included respiratory complications such as pneumonia (fever >38°C, purulent sputum, abnormal findings on chest X-ray), acute respiratory distress syndrome [partial pressure of oxygen in arterial blood (PaO 2 )/fraction of inspired oxygen (FiO 2 ) <200 mmHg], respiratory insufficiency requiring tracheostomy, respiratory failure requiring mechanical ventilation, atelectasis with bronchoscopic intervention, initiation of home oxygen treatment and cardiovascular complications including arrhythmias (atrial fibrillation, paroxysmal supraventricular tachycardia and ventricular tachycardia), angina pectoris, myocardial infarction, congestive heart failure and thromboembolic events. Surgical factors such as prolonged air leaks and bronchopleural fistulas were excluded. Finally, operative mortality was defined as death within 30 days following surgery.
Statistical analysis
Data are presented as the mean ± SD or as the median with interquartile range. Categorical variables are shown as the percentage of the sample. Comparisons between the two groups were assessed by Student's t-tests for normally distributed variables, by the MannWhitney U-test for non-normally distributed variables and by the χ 2 test for categoric variables. All data were analysed with the SPSS statistical software package (version 11.0; IBM Corporation, Armonk, NY, USA). P < 0.05 was considered significant.
RESULTS
Subjects
There were no significant differences between the two groups in baseline characteristics, surgical data, use of catecholamines, pre-operative pulmonary function and serum BNP levels (Table 1) . In both the groups, most patients had one or more major comorbid conditions, most commonly hypertension. Both the groups had relatively higher pre-operative BNP levels and underwent lobectomies in most cases.
Incidence of post-operative cardiopulmonary complications
Post-operative cardiopulmonary complications were identified in 18 (86%) subjects in the control group and 6 (26%) subjects THORACIC in the hANP group ( Table 2 ). The incidence of post-operative cardiopulmonary complications was significantly lower in the hANP group (P < 0.001). The most common complications in both the groups were arrhythmias, and the incidence of cardiovascular complications was significantly lower in the hANP group (P < 0.001). Furthermore, the incidence of respiratory complications was also significantly lower in the hANP group (P < 0.05). Of the four patients with post-operative home oxygen therapy, two patients had pneumonia and one patient had acute respiratory distress syndrome in acute phase after surgery.
Operative mortality
Overall operative mortality was 2.3% (one patient). The cause of death was an acute myocardial infarction in a control group patient.
Haemodynamics
There were no significant differences between the groups in systolic blood pressure, diastolic blood pressure, heart rate and urine volume (Fig. 1) . None of the subjects received a blood transfusion. None of the subjects had the hANP infusion discontinued due to any side effects.
Post-operative white blood cell and C-reactive protein levels
The hANP group had significantly lower WBC counts and CRP levels compared with the control group on Days 3 and 7, as well as 1 month after surgery (Fig. 2) , although the period of hANP infusion was for only 3 days.
DISCUSSION
The present results are the first to show that continuous infusion of low-dose hANP has a prophylactic effect on post-operative cardiopulmonary complications in high-risk elderly patients undergoing pulmonary resection for lung cancer. The infusion of low-dose hANP did not significantly change post-operative haemodynamics and decreased the post-operative WBC and CRP levels, which could suggest attenuation of inflammatory changes associated with the prevention of post-operative cardiopulmonary complications. In the present study, continuous infusion of low-dose hANP was highly tolerable, and no clinically significant adverse effects were observed. The present findings indicate that low-dose hANP administration is a valuable treatment option to prevent post-operative cardiopulmonary complications in high-risk elderly patients undergoing thoracic surgery.
The hANP is considered to have various effects on postoperative cardiopulmonary complications in elderly patients undergoing pulmonary resection. First, it has beneficial effects on haemodynamics and neurohormonal balance. Several studies have shown that infusion of hANP increases stroke volume and decreases pulmonary capillary wedge pressure, improving the haemodynamics and the clinical status in patients with congestive heart failure [7, 15] . However, Sezai et al. [16] reported that low-dose hANP infusion (0.02 μg/kg/min) did not significantly change haemodynamics, but reduce renin activity and angiotensin and aldosterone levels, and it prevented postoperative cardiovascular complications after coronary artery bypass grafting [17] . Consistent with this result, there were no significant differences between the low-dose hANP and control groups in post-operative haemodynamics among patients who underwent pulmonary resection. Furthermore, in this study, post-operative complications, both cardiovascular and respiratory, were significantly lower in the hANP group. These results are also compatible with the data in the cardiovascular field [16] . Evidence has recently been presented that atrial natriuretic peptide (ANP) has a much broader range of biological activities, including the inhibition of inflammation and oxidative stress. Several studies have shown that ANP attenuates several pathways of inflammation in vitro and in vivo model and suggested its role in the regulation of pulmonary function in the setting of acute lung injury and pulmonary inflammation [10, 18] . Xing and Birukova [10] reported that ANP attenuated activation of inflammatory signalling (nuclear factor-kappaB) by lipopolysaccharides and tumour necrosis factoralpha in human pulmonary endothelial cells. Mitaka et al. [18] reported that hANP infusion improved pulmonary gas exchange in patients with acute lung injury during mechanical ventilation. These studies suggest that hANP attenuates systemic inflammatory changes, including pulmonary inflammation, and protects the function of pulmonary endothelial cells after surgery, which might lead to a prophylactic effect for high-risk elderly patients, preventing both cardiovascular and respiratory complications.
Nesiritide, human BNP, is an agent approved for the treatment of symptomatic heart failure in the USA and in some other countries. Recent studies have conflicting conclusions about its effects on renal function [19, 20] . However, Sezai et al. [17] recently reported the safety of low-dose hANP with respect to post-operative renal function, and they found that low-dose hANP significantly reduced serum creatine and creatine clearance when compared with placebo after cardiac surgery. In this study, comparison of the estimated glomerular filtration rate (GFR) showed no significant difference during the perioperative period, and no patients had an increase in serum creatinine >0.5 mg/dl post-operatively in the hANP group (data not shown). This may be explained by the possibility that low-dose hANP did not significantly change haemodynamics and urine output in this population. Finally, it is important to note that the hANP group had significantly lower WBC and CRP levels 1 month after surgery than the control group, while the period of hANP infusion was for only 3 days after operation. We believe that the long-term effects and the prognosis, as well as the mechanism of hANP, should be addressed in further studies.
This study was a two-institution clinical study, which restricted our ability to generalize the results. In addition, patients were not assigned to either group randomly. Furthermore, the number of patients in the study cohort was small. Thus, additional investigations with a larger number of patients from multiple institutions are necessary to allow for generalization of the findings obtained here.
The present study is the first to show prophylactic effects of low-dose hANP on post-operative cardiopulmonary complications without major adverse events in high-risk elderly patients undergoing pulmonary resection for lung cancer. Additional studies are warranted to determine whether these effects can be observed in other patients and translated into improved clinical outcomes. Changes in WBC counts and CRP levels in patients undergoing elective pulmonary resection for lung cancer who did and did not receive hANP. Each point with bars shows the mean ± SD; *P < 0.05, **P < 0.001.
